BioSpace News Archive

Aruna Bio, Inc. today announced that Dr. Mark A. Sirgo, Chief Executive Officer, will be presenting at the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Baidu, Inc. (NASDAQ:BIDU and HKEX:9888), a leading AI company with strong Internet foundation, and Sanofi, a leading biopharmaceutical company focused on human health, have entered into an agreement to integrate Baidu’s messenger ribonucleic acid (mRNA) design optimization platform, LinearDesign, into Sanofi’s product design pipeline.

Sutro Biopharma, Inc. today announced that Chief Executive Officer, Bill Newell , will participate in two upcoming virtual investor conferences.

MGC Diagnostics Corporation (“MGC”), a global medical technology company dedicated to cardiorespiratory health solutions, and a portfolio company of Altus Capital Partners, Inc. (“Altus”), announced today the acquisition of Lemon Medical, GmbH.

BeiGene today announced that the first patient has been dosed in a Phase 1 clinical trial of BGB-23339, a potent, allosteric investigational tyrosine kinase 2 (TYK2) inhibitor internally developed by BeiGene scientists.

Apollomics Inc. today announced that the first patient has been successfully dosed in a Phase 3 clinical trial of APL-106 (uproleselan injection) for the treatment of adults with relapsed or refractory acute myeloid leukemia (AML) in China.

Aligos Therapeutics, Inc. (Nasdaq: ALGS), today announced that Lawrence M. Blatt, Ph.D., MBA, Chairman and CEO of Aligos, will present at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 30 - December 2, 2021.

Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced that members of the senior management team have participated in a fireside chat in advance of the Piper Sandler 33rd Annual Virtual Healthcare Conference.

Potential one-time gene therapy for the treatment of Duchenne, includes a novel, optimized microdystrophin transgene and REGENXBIO’s proprietary NAV ® AAV8 vector Commercial-scale cGMP material to be used in clinical development Company on track to submit IND by end of 2021.

NeoImmuneTech, Inc. today presented data from Phase 1 of an ongoing study at the Society for Neuro-Oncology (SNO) annual meeting.